Already, neuropathology data from ADNI participants have been instrumental in two exciting ADNI biomarker studies: (1) providing “gold standard” evidence of LBD and/or MSA pathology for an evaluation of an alpha‐synuclein seeding assay applied to ADNI CSF samples,34 and (2) contributing ADNI cohort data to a larger study using MRI to detect non‐AD copathologies.35 This evidence concerns the gene SNCA and Alzheimer disease.